希望与意义建构在1期肿瘤试验中:关于患者参与者体验的定性证据的系统综述与主题综合
该系统综述检索MEDLINE、EMBASE、PsycINFO、Scopus、CINAHL和Cochrane CENTRAL等数据库,纳入13项定性研究,采用主题综合法分析患者参与1期肿瘤试验的体验。研究识别出决策与加入试验、参与体验以及希望与应对三大主题,患者多抱有治疗获益的希望,其视角更常指向希望与期望的差异及文化叙事,而非基于理解不足的治疗误解。作者建议在试验前后个性化考虑存在性与生活质量问题,包括姑息与支持治疗替代方案。
要点
- 患者参与1期肿瘤试验主要希望获得治疗获益,这种希望贯穿并塑造其试验旅程体验。
- 患者视角更常指向希望与期望的差异及保持积极、尝试一切、信任专家的文化叙事,而非治疗误解。
- 作者建议在试验前后个性化考虑存在性与生活质量问题,包括姑息与支持治疗替代方案。
核心结论
- 这些发现挑战了基于信息的知情同意模型,支持考虑严重疾病期间希望与意义建构作用的应对框架。
- 作者建议在试验前后个性化考虑存在性与生活质量问题,包括姑息与支持治疗替代方案。
研究设计与样本
- 系统综述与主题综合,检索MEDLINE、EMBASE、PsycINFO、Scopus、CINAHL和Cochrane CENTRAL数据库,并辅以补充检索。
- 由两名研究者独立筛选纳入研究,使用标准化表格进行批判性评价和数据提取,纳入13项定性研究。
- 综述已在PROSPERO国际前瞻性系统综述注册平台注册(CRD 42020163250)。
主要发现
- 在13项研究中识别出三大主题:决策与加入试验;参与试验的体验;希望与应对。
- 患者主要希望获得治疗获益而加入试验,这种情感贯穿并塑造其整个试验旅程的体验。
- 患者视角更常指向希望与期望之间的差异以及保持积极、尝试一切和信任专家的文化叙事,而非表明基于理解不足的治疗误解。
临床怎么用
- 作者建议在试验前后个性化考虑存在性与生活质量问题,包括姑息与支持治疗替代方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phase 1 drug trials are popular treatment options for patients with advanced disease, despite the greater levels of uncertainty associated with them. However, their meaning and consequences for patient-participants remains under-explored. This review synthesises the qualitative evidence of patients' experiences of participating in phase 1 oncology trials, exploring their decisions to take part and the impacts of these trials on patient wellbeing. METHODS: A comprehensive literature search involving medical subject headings (MeSH) and keywords was undertaken in the following databases: MEDLINE, EMBASE, PsycINFO, Scopus, CINAHL, and Cochrane CENTRAL, with supplementary searches also conducted. Studies were independently screened for inclusion by two researchers. Included studies were critically appraised and data extracted using standardised forms. Qualitative results were analysed using thematic synthesis. RESULTS: Three main themes were identified across 13 studies: decision-making and joining the trial; experiences of taking part in the trial and hope and coping. Patients primarily joined trials hoping for therapeutic benefits, sentiments which prevailed and shaped their experiences across their trial journey. Rather than indicate therapeutic misconception based on poor understanding, patient perspectives more commonly pointed to differences between hope and expectation and cultural narratives of staying positive, trying everything and trusting in experts. CONCLUSIONS: These findings challenge information-based models of consent, favouring coping frameworks which account for the role of hope and meaning-making during serious illness. Personalised consideration of existential and quality-of-life matters before and during trials is recommended, including palliative and supportive care alternatives to active treatment. REVIEW REGISTRATION: The review was registered with PROSPERO international prospective register of systematic reviews (CRD 42020163250).
引用
- Escritt K, Mann M, Nelson A, et al. Hope and meaning-making in phase 1 oncology trials: a systematic review and thematic synthesis of qualitative evidence on patient-participant experiences. Trials. 2022. PMID: 35578308. doi:10.1186/s13063-022-06306-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。